Hong Kong · Delayed Price · Currency is HKD CF PharmTech Statistics
Total Valuation
CF PharmTech has a market cap or net worth of HKD 4.47 billion. The enterprise value is 4.14 billion.
| Market Cap | 4.47B |
| Enterprise Value | 4.14B |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CF PharmTech has 406.36 million shares outstanding. The number of shares has increased by 7.21% in one year.
| Current Share Class | 296.61M |
| Shares Outstanding | 406.36M |
| Shares Change (YoY) | +7.21% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.31% |
| Owned by Institutions (%) | 10.10% |
| Float | 221.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.86 |
| PB Ratio | 2.88 |
| P/TBV Ratio | 3.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.21 |
| EV / EBITDA | 60.36 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.21 |
| Quick Ratio | 2.80 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 3.50 |
| Debt / FCF | n/a |
| Interest Coverage | -2.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -0.56% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 806,830 |
| Profits Per Employee | -12,544 |
| Employee Count | 625 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -17.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 14.79 |
| 200-Day Moving Average | 24.40 |
| Relative Strength Index (RSI) | 37.26 |
| Average Volume (20 Days) | 3,512,978 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CF PharmTech had revenue of HKD 504.27 million and -7.84 million in losses. Loss per share was -0.02.
| Revenue | 504.27M |
| Gross Profit | 384.31M |
| Operating Income | -9.62M |
| Pretax Income | -25.28M |
| Net Income | -7.84M |
| EBITDA | 65.23M |
| EBIT | -9.62M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 576.65 million in cash and 245.12 million in debt, with a net cash position of 331.53 million or 0.82 per share.
| Cash & Cash Equivalents | 576.65M |
| Total Debt | 245.12M |
| Net Cash | 331.53M |
| Net Cash Per Share | 0.82 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 3.81 |
| Working Capital | 614.05M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 75.92M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 76.21%, with operating and profit margins of -1.91% and -1.55%.
| Gross Margin | 76.21% |
| Operating Margin | -1.91% |
| Pretax Margin | -5.01% |
| Profit Margin | -1.55% |
| EBITDA Margin | 12.94% |
| EBIT Margin | -1.91% |
| FCF Margin | n/a |
Dividends & Yields
CF PharmTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.21% |
| Shareholder Yield | -7.21% |
| Earnings Yield | -0.18% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |